C12N 2710/24061
Methods of inactivation or attenuation
C12N2710/24061 (Methods of inactivation or attenuation) appears on 9 US grants and 13 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 13
- Assignees
- 9
- Inventors
- 26
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 1 | 0 |
| 2013 | 1 | 2 |
| 2014 | 1 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 1 | 0 |
| 2018 | 2 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 1 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods for inducing an enhanced immune response using poxvirus vectors2 Jun 2026US 12,644,125 B2Bavarian Nordic A/S
- NYVAC-based plasmodium malaria vaccine25 May 2021US 11,013,791 B2The Government of the United States, as represented by the Secretary of the Army
- Inactivating pathogens with oxidizing agents for vaccine production4 Dec 2018US 10,143,740 B2Oregon Health & Science University
- Myxoma virus mutants for cancer treatment29 May 2018US 9,980,994 B2Robarts Research Institute
- MVA virus and uses thereof15 Aug 2017US 9,732,325 B2Probiogen AG
- Oncolytic viruses that express multi-specific immune cell engagers21 Mar 2024US 2024/0093158 A1Arizona Board of Regents on behalf of Arizona State University
- Compositions and Methods for Inducing an Enhanced Immune Response Using Poxvirus Vectors15 Oct 2020US 2020/0325477 A1Bavarian Nordic A/S
- Nyvac-based plasmodium malaria vaccine14 May 2020US 2020/0147196 A1Government of the United States of America, AS Represented By the Secretary of the Army
- Compositions and methods for inducing an enhanced immune response using poxvirus vectors29 Dec 2016US 2016/0376596 A1Bavarian Nordic A/S
- Myxoma virus mutants for cancer treatment19 May 2016US 2016/0136212 A1Robarts Research Institute
Most cited
By later US patents
- Inactivating pathogens with oxidizing agents for vaccine production8US 8,124,397 B2Oregon Health & Science University · 2012
- Inactivating pathogens with oxidizing agents for vaccine production6US 8,716,000 B2Oregon Health & Science University · 2014
- Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses4US 5,989,561 AVirogenetics Corporation · 1999
- Myxoma virus mutants for cancer treatment2US 8,512,713 B2Robarts Research Institute · 2013